Shots:
- The US FDA has approved Keytruda Qlex (pembrolizumab & berahyaluronidase alfa-pmph) for subcutaneous dosing in adults across 38 approved indications of Keytruda, with US availability expected by late Sep 2025
- Approval was based on P-III (3475A-D77) trial assessing Keytruda Qlex (790mg/9600 units, Q6W) + Pt doublet CT vs IV Keytruda (400mg, Q6W) + Pt doublet CT in 1L metastatic NSCLC adults (n=377) with no EGFR, ALK or ROS1 mutations
- Trial showed that Keytruda Qlex is noninferior to Keytruda in AUC exposure & Ctrough, plus achieved ORR of 45% vs 42%, with comparable PFS & OS observed between the two
Ref: Merck | Image: Merck | Press Release
Related News:- The CHMP Adopts Positive Opinion on Merck’s Enflonsia for RSV Prevention in Infants
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
